IN THE UNITED STATES PATENT AND TRADEMARK OFFICE In re Patent Application of Attv MJW-39-187 Dkt M# C# BLAKE et al TC/A.U. 1625 Serial No 09/367 261 Examiner: Dentz. B. Filed: August 10, 2001 Date: March 23, 2010 Title: DRUG TARGETING Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir INFORMATION DISCLOSURE STATEMENT This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon. Correspondence Address Indication Form Attached. Fees are attached as calculated below: Total effective claims after amendment n minus highest number previously paid for (at least 20) = Ω x \$52.00 \$0.00 (1202)/\$0.00 (2202) \$ 0.00 Independent claims after amendment minus highest number previously paid for 3 (at least 3) = x \$220.00 \$0.00 (1201)/\$0.00 (2201) \$ 0.00 If proper multiple dependent claims now added for first time, (ignore improper); add \$390,00 (1203)/\$195.00 (2203) \$ 0.00 Petition is hereby made to extend the current due date so as to cover the filing date of this One Month Extension \$130.00 (1251)/\$65.00 (2251) paper and attachment(s) Two Month Extensions \$490.00 (1252)/\$245.00 (2252) Three Month Extensions \$1110.00 (1253/\$555.00 (2253) Four Month Extensions \$1730.00 (1254/\$865.00 (2254) Five Month Extensions \$2350.00 (1255/\$1175.00 (2255) \$ 0.00 Terminal disclaimer enclosed, add \$140.00 (1814)/\$70.00 (2814) \$ 0.00 Applicant claims "small entity" status. Statement filed herewith Rule 56 Information Disclosure Statement Filing Fee 180.00 \$180.00 (1806) S Assignment Recording Fee \$40.00 (8021) \$ 0.00 Other: s 0.00 TOTAL FEE S 180 00 CREDIT CARD PAYMENT.

The Commissioner is hereby authorized to charge any <u>deficiency</u>, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm! to our Account No. 14-1140.

901 North Glebe Road, 11th Floor Arlington, Virginia 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

M.IW tat

NIXON & VANDERHYE P.C.

By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: /Mary J. Wilson/

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of		Confirmation No. 4136	
BLAKE et al		Atty. Ref.: 3	39-187
Serial No. 09/	/367,261	Group:	1625
Filed: August	t 10, 2001	Examiner: [	Dentz, B.
For: DRUG TARGETING			
	* * * * * * * *	* * *	
Commissioner for Patents March 23, 201 P.O. Box 1450 Alexandria, VA 22313-1450			10
Sir:	INFORMATION DISCLOSURE S	TATEMENT	
	O/SB/08a Pursuant to 37 CFR 1.97( thin 3 months of filing or prior to 1st C		n the merits] <i>N/</i> C
[bet	Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)]  N/C		
[bet	Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] \$180.00		
[afte	rsuant to 37 CFR 1.97(d) er Final Office Action or Allowance (r ttement <u>and</u> Rule 17(p) fee), but befo		
The following are submitted in the above-identified application in compliance			

e with 37 C.F.R. §§ 1.97 and 1.98:

⊠ 4. A list of documents on Form PTO/SB/08a together with copies (as may be required) of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with: 37 CFR 1.97(b): [within 3 months of filling or prior to 1st Office Action] 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]: and a) The required Statement made in item 8 below; or b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below. 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee paymentl; and a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith: and b) The required Statement is stated in item 8 below. 8. Statement under 37 CFR 1.97(e) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement  $\boxtimes$ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this

application to Deposit Account No. 14-1140.

Respectfully submitted, NIXON & VANDERHYE P.C.

By: /Mary J. Wilson/
Mary J. Wilson
Reg. No. 32,955

901 North Glebe Road, 11th Floor Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100